Archived Medical News Stories

RSSArchived Drug Trial News Stories - September 2011

Date Title Comments Rating
2011-09-30 Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J. 0 None
2011-09-30 Cincinnati Children's to conduct first medication clinical trial for pediatric migraine 0 None
2011-09-30 Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC 0 5
2011-09-30 Small Phase I trial shows HIV vaccine candidate is most powerful to date 0 None
2011-09-30 Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated 0 None
2011-09-29 Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors 0 None
2011-09-29 Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease 0 None
2011-09-29 Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD 0 None
2011-09-29 DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials 0 5
2011-09-29 Cincinnati Children's to conduct first pediatric migraine medicine clinical trial 0 None
2011-09-29 Almirall submits linaclotide MAA to EMA for treatment of IBS-C 0 None
2011-09-29 VOICE HIV prevention trial to discontinue use of tenofovir tablets 0 None
2011-09-29 Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer 0 None
2011-09-29 SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke 0 4
2011-09-28 Halozyme commences HTI-501 clinical trial for cellulite in women 0 None
2011-09-28 Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV 0 None
2011-09-28 Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease 0 1
2011-09-28 YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis 0 None
2011-09-28 Lovastatin appears to be safe, effective for children with neurofibromatosis type 1 0 None
2011-09-28 BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR 0 2.7
2011-09-28 MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus 0 None
2011-09-27 22nd Century completes enrollment in X-22 Phase II-B smoking cessation study 0 None
2011-09-27 The Nation examines rise in unregulated drug trials in South America 0 None
2011-09-27 HCRI completes enrollment in dual antiplatelet therapy clinical trial 0 None
2011-09-27 Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program 0 None
2011-09-27 Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program 0 None
2011-09-27 Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting 0 None
2011-09-27 Novartis files marketing authorisation with EMA for NVA237 to treat COPD 0 None
2011-09-27 Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011 0 None
2011-09-27 Zoledronic acid may extend survival in older breast cancer patients 0 None
2011-09-27 Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors 0 None
2011-09-27 Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia 0 None
2011-09-27 Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study 0 None
2011-09-26 Smaller and faster clinical drug trials could improve gains in cancer survival 0 None
2011-09-26 Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting 0 None
2011-09-26 Zoledronic acid may benefit post-menopausal women with breast cancer 0 None
2011-09-26 Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL 1 None
2011-09-26 Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer 0 None
2011-09-26 JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME 0 None
2011-09-26 Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma 0 None
2011-09-26 Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL 0 None
2011-09-26 Ibandronate controls pain in prostate cancer patients with bone metastases 0 None
2011-09-26 InterMune reports new data from Esbriet clinical trial on IPF 0 None
2011-09-26 Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC 0 None
2011-09-26 Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint 0 None
2011-09-26 Combination of Afinitor, exemestane reduces risk of breast cancer progression in women 0 None
2011-09-26 Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials 0 None
2011-09-26 Combination of abiraterone acetate, prednisone reduces fatigue in men with prostate cancer 0 1
2011-09-26 Breast cancer drug combination could stop cancer “in its tracks” 0 None
2011-09-26 Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer 0 None
2011-09-26 Combination of chemo and radiotherapy in breast cancer: Trial 0 None
2011-09-26 Drug combo for breast cancer in post-menopausal women shows promise 0 None
2011-09-26 Zometa bone drug trial in post-menopausal women with breast cancer 0 None
2011-09-26 Embryonic stem cell therapy for incurable Stargardt eye disease 2 3.5
2011-09-26 The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study 0 None
2011-09-26 First Radium-223 Chloride Phase III study in prostate cancer 0 None
2011-09-26 Combination of everolimus, exemestane holds promise against post-menopausal breast cancer 0 None
2011-09-26 RegeneRx completes RGN-259 Phase 2 trial on dry eye syndrome 0 None
2011-09-26 Letrozole reduces risk of breast cancer recurrences and death in post-menopausal women 0 None
2011-09-23 EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection 0 None
2011-09-23 YM BioSciences total revenue decreases to $1.5 million for fiscal 2011 0 None
2011-09-23 Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011 0 None
2011-09-23 Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV 0 None
2011-09-23 E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug 0 None
2011-09-23 Soy protein reduces progression of atherosclerosis in women within 5 years of menopause 0 None
2011-09-23 Researchers to expand malaria vaccine study after initial trial yields encouraging results 0 None
2011-09-23 Researchers compare safety and effectiveness of cryotherapy, salicylic acid for verrucae 0 None
2011-09-23 Levosimendan may effectively improve muscle function in patients with respiratory failure 0 None
2011-09-23 Preclinical data from two Pulmatrix's PUR118 study to be presented at ERS 2011 0 None
2011-09-22 Acetylon initiates ACY-1215 Phase 1-2a clinical trial for multiple myeloma 0 None
2011-09-22 Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC 0 None
2011-09-22 Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis 0 None
2011-09-22 Theraclone initiates TCN-032 Phase 1 trial in influenza A 0 None
2011-09-22 NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF 0 None
2011-09-22 S-equol improve appearance of crow's feet skin wrinkles in Japanese menopausal women 0 None
2011-09-21 HRPR before PCI procedures linked to increased risk of ischemic event in ACS patients 0 None
2011-09-21 Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD 0 None
2011-09-21 Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA 0 None
2011-09-21 Positive results from Orexo's OX219 clinical study on opioid dependence 0 None
2011-09-20 Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339 0 None
2011-09-20 Gilead’s new 4 in 1 combo HIV pill works 0 None
2011-09-20 U-M Professor to review data from three prominent studies on heart failure 0 None
2011-09-20 Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective 0 None
2011-09-20 New research has potential to alleviate side effects of cancer treatments 0 None
2011-09-20 Tokai raises $23M in Series D3 financing 0 None
2011-09-20 Major donors should consider funding for potential malaria vaccine 0 None
2011-09-20 Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis 0 None
2011-09-20 Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia 0 5
2011-09-20 Infant formulas fortified with LCPUFA are good for developing brains and hearts 0 None
2011-09-20 LA BioMed andrologist leads new male contraceptive Phase I clinical study 0 None
2011-09-20 Scientists pioneer new combination treatment for prostate cancer 0 None
2011-09-20 Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC 0 None
2011-09-19 Preclinical studies shows EmPAC more effective than Taxol 0 None
2011-09-19 Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD 0 None
2011-09-19 Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC 0 None
2011-09-19 Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis 1 5
2011-09-19 Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma 0 None
2011-09-19 Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients 0 None
2011-09-19 Aestus to develop ATx09-002 for treatment of neuropathic pain 0 None
2011-09-19 Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia 0 None
2011-09-19 Karo Bio receives approval to initiate eprotirome phase III study in HeFH 0 None
2011-09-19 NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting 0 None
2011-09-19 Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis 0 None
2011-09-17 Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis 0 None
2011-09-17 Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC 0 None
2011-09-17 Multiple abstracts on QNEXA presented at 47th EASD 0 None
2011-09-17 DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain 0 None
2011-09-17 BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine 0 None
2011-09-16 ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes 0 None
2011-09-16 Linagliptin demonstrates durable reductions in blood glucose for T2D adults 0 None
2011-09-16 Combination of prasugrel plus ASA can treat acute coronary syndrome 0 None
2011-09-16 Anavex announces ANAVEX pre-clinical data on Alzheimer's disease 0 None
2011-09-16 Potential new treatment for fragile X syndrome 0 None
2011-09-16 Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients 0 5
2011-09-16 Experimental malaria vaccine shows positive results among children in small Burkina Faso study 0 None
2011-09-16 Probiotics appear to protect against upper respiratory tract infections 0 None
2011-09-16 Azithromycin gel may treat borreliosis in humans 0 None
2011-09-16 Diclofenac in nano-formulated doses provides effective pain relief 0 None
2011-09-15 CRF announces late breaking trials & first report investigations to be presented at TCT 2011 0 None
2011-09-15 Anavex Life Sciences to present data on lead compound for Alzheimer’s at Japan Neuroscience Society 0 None
2011-09-15 International patient groups anxiously await start of Huntington’s trial 0 5
2011-09-15 KAI enters KAI-4169 development and commercialization agreement with Ono 0 None
2011-09-15 Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment 0 None
2011-09-15 NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma 0 None
2011-09-15 Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes 0 5
2011-09-15 Patients with hepatitis C may benefit from 24 week telaprevir-based regimen 0 None
2011-09-15 Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis 0 None
2011-09-15 First effective blood-stage vaccine against malaria 0 5
2011-09-15 NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C 0 None
2011-09-15 SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease 0 None
2011-09-15 Scientist granted over $138,000 to explore Vitamin C therapy in sepsis 0 5
2011-09-15 Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes 0 None
2011-09-14 Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections 0 None
2011-09-14 Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer 0 None
2011-09-14 Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study 0 None
2011-09-14 New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011 0 None
2011-09-14 Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma 0 None
2011-09-14 Lexicon's LX4211 clinical data presented at EASD annual meeting 0 None
2011-09-14 VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting 0 None
2011-09-14 ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE 0 None
2011-09-14 Acceleron commences ACE-536 Phase 1 clinical trial in anemia 0 None
2011-09-13 New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress 0 None
2011-09-13 Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib 0 None
2011-09-13 Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference 0 None
2011-09-13 ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM 0 None
2011-09-12 Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease 0 4.3
2011-09-12 Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin 0 None
2011-09-12 Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer 0 None
2011-09-12 BioSante reports top-line results from LibiGel PK study for HSDD in postmenopausal women 0 None
2011-09-12 Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease 0 None
2011-09-12 Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC 0 3
2011-09-12 InteRNA, Silence partner to develop novel microRNA therapeutics for cancer 0 None
2011-09-12 Recruitment complete in Moberg Derma's MOB-015 phase II study for nail fungus 1 None
2011-09-12 Roche initiates Phase 1 clinical trial of investigational drug for Down syndrome 0 5
2011-09-12 UMSOM to receive FDA approval for whole parasite malaria vaccine clinical trials 0 None
2011-09-12 Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer 0 None
2011-09-09 Fewer doses of Cervarix vaccine may be as efficacious as standard three-dose regimen 0 None
2011-09-09 Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban 0 None
2011-09-09 Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction 0 None
2011-09-09 Positive results from Sanaria PfSPZ Vaccine initial Phase 1 trial on malaria 0 None
2011-09-08 OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials 0 None
2011-09-08 Lilly, Boehringer Ingelheim to present latest data from diabetes portfolio at 47th EASD meeting 0 None
2011-09-08 Better communication needed with at-risk communities for HIV vaccine trials 0 None
2011-09-08 Adding azithromycin to usual daily treatment for COPD reduces acute exacerbations by 27% 0 None
2011-09-07 Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD 0 None
2011-09-07 Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA 0 None
2011-09-07 Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects 0 None
2011-09-07 Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma 0 None
2011-09-07 ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme 0 None
2011-09-07 GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052 0 None
2011-09-07 Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data 0 None
2011-09-06 Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence 0 None
2011-09-06 Enrollment complete in DURECT's POSIDUR Phase III study for post-surgical pain 0 None
2011-09-06 Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints 0 None
2011-09-06 Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease 0 None
2011-09-06 ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL 0 None
2011-09-06 Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1 0 None
2011-09-06 NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease 0 None
2011-09-06 Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma 0 None
2011-09-06 Chondroitin sulfate decreases pain and improves hand function in patients with OA 0 None
2011-09-06 BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer 0 None
2011-09-05 Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks 0 None
2011-09-05 Gilead to amend design of ongoing clinical trials against chronic hepatitis C 0 None
2011-09-03 SWOG selects four cancer researchers for 2011 Young Investigator Training Course 0 None
2011-09-02 Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia 0 None
2011-09-02 New meta-analysis reaffirms safety profile of aspirin for pain relief, fever 0 None
2011-09-02 Valproic acid may increase survival for brain tumor patients 0 None
2011-09-02 New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress 1 None
2011-09-02 UTHealth to study BMS-820836 in Phase II trial for major depressive disorder 0 None


189 posts
25 raters